Ron Waksman1, Rebecca Torguson2, Mia-Ashley Spad2, Hector Garcia-Garcia2, James Ware3, Rui Wang3, Sean Madden4, Priti Shah4, James Muller5. 1. MedStar Washington Hospital Center, Section of Interventional Cardiology, Washington, DC. Electronic address: ron.waksman@medstar.net. 2. MedStar Washington Hospital Center, Section of Interventional Cardiology, Washington, DC. 3. Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, MA. 4. Infraredx, Burlington, MA. 5. Brigham and Women's Hospital, Division of Cardiovascular Medicine, Boston, MA.
Abstract
BACKGROUND: It has been hypothesized that the outcome post-PCI could be improved by the detection and subsequent treatment of vulnerable patients and lipid-rich vulnerable coronary plaques (LRP). A near-infrared spectroscopy (NIRS) catheter capable of detecting LRP is being evaluated in The Lipid-Rich Plaque Study. STUDY DESIGN: The LRP Study is an international, multicenter, prospective cohort study conducted in patients with suspected coronary artery disease (CAD) who underwent cardiac catheterization with possible ad hoc PCI for an index event. Patient level and plaque level events were detected by follow-up in the subsequent 2 years. Enrollment began in February 2014 and was completed in March 2016; a total of 1,562 patients were enrolled. Adjudication of new coronary event occurrence and de novo culprit lesion location during the 2-year follow-up is performed by an independent clinical end-points committee (CEC) blinded to NIRS-IVUS findings. The first analysis of the results will be performed when at least 20 de novo events have occurred for which follow-up angiographic data and baseline NIRS-IVUS measurements are available. It is expected that results of the study will be announced in 2018. SUMMARY: The LRP Study will test the hypotheses that NIRS-IVUS imaging to detect LRP in patients can identify vulnerable patients and vulnerable plaques. Identification of vulnerable patients will assist future studies of novel systemic therapies; identification of localized vulnerable plaques would enhance future studies of possible preventive measures.
BACKGROUND: It has been hypothesized that the outcome post-PCI could be improved by the detection and subsequent treatment of vulnerable patients and lipid-rich vulnerable coronary plaques (LRP). A near-infrared spectroscopy (NIRS) catheter capable of detecting LRP is being evaluated in The Lipid-Rich Plaque Study. STUDY DESIGN: The LRP Study is an international, multicenter, prospective cohort study conducted in patients with suspected coronary artery disease (CAD) who underwent cardiac catheterization with possible ad hoc PCI for an index event. Patient level and plaque level events were detected by follow-up in the subsequent 2 years. Enrollment began in February 2014 and was completed in March 2016; a total of 1,562 patients were enrolled. Adjudication of new coronary event occurrence and de novo culprit lesion location during the 2-year follow-up is performed by an independent clinical end-points committee (CEC) blinded to NIRS-IVUS findings. The first analysis of the results will be performed when at least 20 de novo events have occurred for which follow-up angiographic data and baseline NIRS-IVUS measurements are available. It is expected that results of the study will be announced in 2018. SUMMARY: The LRP Study will test the hypotheses that NIRS-IVUS imaging to detect LRP in patients can identify vulnerable patients and vulnerable plaques. Identification of vulnerable patients will assist future studies of novel systemic therapies; identification of localized vulnerable plaques would enhance future studies of possible preventive measures.
Authors: Alberto Boi; Ankush D Jamthikar; Luca Saba; Deep Gupta; Aditya Sharma; Bruno Loi; John R Laird; Narendra N Khanna; Jasjit S Suri Journal: Curr Atheroscler Rep Date: 2018-05-21 Impact factor: 5.113
Authors: Frans B Mensink; Tim J F Ten Cate; Sander A J Damen; Kit Roes; Carlo Di Mario; Varinder Singh; Ziad A Ali; William Skinner; Andre Artis; Rebecca Torguson; Cheng Zhang; Gheorghe Doros; Hector M Garcia-Garcia; Gary S Mintz; Robert-Jan van Geuns; Ron Waksman Journal: Int J Cardiol Heart Vasc Date: 2022-03-08